{"filing":{"accession_number":"0001213900-26-110813","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"ea0309123-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026110813/ea0309123-6k_radiopharm.htm"},"events":[{"id":36230,"run_id":33395,"accession_number":"0001213900-26-110813","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"summary":"Four directors (Bruce Goodwin, Ian Turner, Paul Hopper, and Riccardo Canevari) cancelled listed options expiring 31 July 2029 with an exercise price of $0.018 on 16 October 2026, with no consideration paid. These routine ASX-mandated Change of Director's Interest Notices (Appendix 3Y forms) disclose director shareholding changes required under Australian securities law.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-10-20","form":"6-K","submitted_at":null,"items":[{"id":40568,"accession_number":"0001213900-26-110813","item_number":"EX-99.1","item_title":"ea030912301ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit comprises four ASX-mandated \"Change of Director's Interest Notices\" (Appendix 3Y forms) filed under ASX Listing Rule 3.19A.2 for directors Bruce Goodwin, Ian Turner, Paul Hopper, and Riccardo Canevari. Each notice discloses the cancellation of listed options (expiring 31 July 2029, exercise price $0.018) on 16 October 2026, with no consideration paid. These are routine administrative disclosures of director shareholding changes required by Australian securities law, not material events affecting investor assessment of the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:09:40.604640+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":36231,"run_id":33395,"accession_number":"0001213900-26-110813","anchor_item_number":"EX-99.2","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The company issued 140,028,000 unquoted options under the Omnibus Incentive Plan employee incentive scheme, with key management personnel Dimitris Voliotis receiving 30,887,000 of these options. This compensatory arrangement was disclosed via ASX Appendix 3G notification.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-10-20","form":"6-K","submitted_at":null,"items":[{"id":40569,"accession_number":"0001213900-26-110813","item_number":"EX-99.2","item_title":"ea030912301ex99-2.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This is an ASX Appendix 3G notification of the issuance of 140,028,000 unquoted options under an employee incentive scheme (the Omnibus Incentive Plan). Notably, key management personnel Dimitris Voliotis received 30,887,000 of these options. The disclosure explicitly states these are \"securities issued under an employee incentive scheme\" and identifies KMP recipients, making this a compensatory arrangement disclosure under executive compensation rather than a routine dilutive issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:09:40.604640+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40568,"accession_number":"0001213900-26-110813","item_number":"EX-99.1","item_title":"ea030912301ex99-1.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This exhibit comprises four ASX-mandated \"Change of Director's Interest Notices\" (Appendix 3Y forms) filed under ASX Listing Rule 3.19A.2 for directors Bruce Goodwin, Ian Turner, Paul Hopper, and Riccardo Canevari. Each notice discloses the cancellation of listed options (expiring 31 July 2029, exercise price $0.018) on 16 October 2026, with no consideration paid. These are routine administrative disclosures of director shareholding changes required by Australian securities law, not material events affecting investor assessment of the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:09:40.604640+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-10-20"},{"id":40569,"accession_number":"0001213900-26-110813","item_number":"EX-99.2","item_title":"ea030912301ex99-2.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"This is an ASX Appendix 3G notification of the issuance of 140,028,000 unquoted options under an employee incentive scheme (the Omnibus Incentive Plan). Notably, key management personnel Dimitris Voliotis received 30,887,000 of these options. The disclosure explicitly states these are \"securities issued under an employee incentive scheme\" and identifies KMP recipients, making this a compensatory arrangement disclosure under executive compensation rather than a routine dilutive issuance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T10:09:40.604640+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-10-20"}]}